


PHARMACEUTICAL 2019


Edesa Biotech Inc. Rank 168 of 371













The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 260% points. The greatest weakness of Edesa Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is -131%, being 200% points above the market average of -331%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 10,656 |
| Cost of Goods Sold | 133 |
| Intangible Assets | 0 |
| Liabilities, Current | 493 |
| Liabilities, Non-Current | 0 |
| Other Assets | 62 |
| Other Compr. Net Income | 0 |
| Other Expenses | 313 |
| Other Liabilities | 0 |
| Other Net Income | 40 |
| Property and Equipment | 1,062 |
| Research and Development | 2,087 |
| Revenues | 212 |
| Selling, General and Administrative Expense | 2,757 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 11,780 |
| Liabilities | 493 |
| Expenses | 5,291 |
| Stockholders Equity | 11,287 |
| Net Income | -5,039 |
| Comprehensive Net Income | -5,039 |
| Economic Capital Ratio | -131% |

